BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20018353)

  • 1. ERG rearrangement metastasis patterns in locally advanced prostate cancer.
    Perner S; Svensson MA; Hossain RR; Day JR; Groskopf J; Slaughter RC; Jarleborn AR; Hofer MD; Kuefer R; Demichelis F; Rickman DS; Rubin MA
    Urology; 2010 Apr; 75(4):762-7. PubMed ID: 20018353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.
    Barry M; Perner S; Demichelis F; Rubin MA
    Urology; 2007 Oct; 70(4):630-3. PubMed ID: 17991527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.
    Guo CC; Wang Y; Xiao L; Troncoso P; Czerniak BA
    Hum Pathol; 2012 May; 43(5):644-9. PubMed ID: 21937078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.
    Esgueva R; Perner S; J LaFargue C; Scheble V; Stephan C; Lein M; Fritzsche FR; Dietel M; Kristiansen G; Rubin MA
    Mod Pathol; 2010 Apr; 23(4):539-46. PubMed ID: 20118910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERG rearrangement is present in a subset of transition zone prostatic tumors.
    Falzarano SM; Navas M; Simmerman K; Klein EA; Rubin MA; Zhou M; Magi-Galluzzi C
    Mod Pathol; 2010 Nov; 23(11):1499-506. PubMed ID: 20693982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis.
    Gao X; Li LY; Zhou FJ; Xie KJ; Shao CK; Su ZL; Sun QP; Chen MK; Pang J; Zhou XF; Qiu JG; Wen XQ; Yang M; Bai XZ; Zhang H; Ling L; Chen Z
    Clin Cancer Res; 2012 Aug; 18(15):4163-72. PubMed ID: 22696228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing mutual exclusivity of ETS rearranged prostate cancer.
    Svensson MA; LaFargue CJ; MacDonald TY; Pflueger D; Kitabayashi N; Santa-Cruz AM; Garsha KE; Sathyanarayana UG; Riley JP; Yun CS; Nagy D; Kosmeder JW; Pestano GA; Tewari AK; Demichelis F; Rubin MA
    Lab Invest; 2011 Mar; 91(3):404-12. PubMed ID: 20975660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer.
    Braun M; Scheble VJ; Menon R; Scharf G; Wilbertz T; Petersen K; Beschorner C; Reischl M; Kuefer R; Schilling D; Stenzl A; Kristiansen G; Rubin MA; Fend F; Perner S
    Histopathology; 2011 Jun; 58(7):1028-36. PubMed ID: 21707704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center.
    Nie L; Pan X; Zhang M; Yin X; Gong J; Chen X; Xu M; Zhou Q; Chen N
    Prostate; 2019 Jun; 79(8):819-825. PubMed ID: 30900303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERG and CHD1 heterogeneity in prostate cancer: use of confocal microscopy in assessment of microscopic foci.
    Tereshchenko IV; Zhong H; Chekmareva MA; Kane-Goldsmith N; Santanam U; Petrosky W; Stein MN; Ganesan S; Singer EA; Moore D; Tischfield JA; DiPaola RS
    Prostate; 2014 Nov; 74(15):1551-9. PubMed ID: 25175909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.
    Gopalan A; Leversha MA; Satagopan JM; Zhou Q; Al-Ahmadie HA; Fine SW; Eastham JA; Scardino PT; Scher HI; Tickoo SK; Reuter VE; Gerald WL
    Cancer Res; 2009 Feb; 69(4):1400-6. PubMed ID: 19190343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.
    Dong J; Xiao L; Sheng L; Xu J; Sun ZQ
    Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer.
    Kluth M; Meyer D; Krohn A; Freudenthaler F; Bauer M; Salomon G; Heinzer H; Michl U; Steurer S; Simon R; Sauter G; Schlomm T; Minner S
    Oncotarget; 2016 Jan; 7(4):3897-904. PubMed ID: 26684029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.
    Braun M; Goltz D; Adler D; Vogel W; Böhm D; Scheble V; Sotlar K; Fend F; Tan SH; Dobi A; Kristiansen G; Wernert N; Perner S
    Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):165-9. PubMed ID: 22231490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry.
    Falzarano SM; Zhou M; Carver P; Tsuzuki T; Simmerman K; He H; Magi-Galluzzi C
    Virchows Arch; 2011 Oct; 459(4):441-7. PubMed ID: 21773753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
    Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCR4 mRNA overexpression in high grade prostate tumors: lack of association with TMPRSS2-ERG rearrangement.
    de Muga S; Hernández S; Salido M; Lorenzo M; Agell L; Juanpere N; Lorente JA; Serrano S; Lloreta J
    Cancer Biomark; 2012-2013; 12(1):21-30. PubMed ID: 23321466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
    Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
    Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
    Darnel AD; Lafargue CJ; Vollmer RT; Corcos J; Bismar TA
    Cancer Biol Ther; 2009 Jan; 8(2):125-30. PubMed ID: 19029822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.
    Scheble VJ; Braun M; Beroukhim R; Mermel CH; Ruiz C; Wilbertz T; Stiedl AC; Petersen K; Reischl M; Kuefer R; Schilling D; Fend F; Kristiansen G; Meyerson M; Rubin MA; Bubendorf L; Perner S
    Mod Pathol; 2010 Aug; 23(8):1061-7. PubMed ID: 20473283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.